These findings further corroborate prior trial data demonstrating that Mayzent use delays disability progression and cognitive decline in SPMS patients.
The results were disclosed at the 2019 Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), which ran Sept. 11-13 in Stockholm, Sweden. The presentation, titled “Siponimod delays the time to wheelchair in patients with SPMS: results from the EXPAND study,” was given by Patrick Vermersch, MD, PhD, neurologist and researcher at the University of Lille, France.
SPMS is characterized by steadily worsening disease, including the progressive loss of walking ability.
“Worsening of ambulation is one of the key features of SPMS, which eventually leads to increased dependence on a wheelchair in a large number of patients,” Vermersch said.
Novartis‘ Mayzent is a sphingosine-1-phosphate (S1P) receptor modulator for the treatment of adults with relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome (CIS), relapsing-remitting MS (RRMS), and active SPMS.
The FDA’s decision was based, in part, on data from the EXPAND Phase 3 clinical trial (NCT01665144). That data showed that SMPS patients taking oral Mayzent experienced a decrease in disability progression and in cognitive decline.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?